Cancer stroma‐targeting therapy: A new tool for fighting pancreatic cancer?

Recent advances in multimodal treatment, including surgery, chemotherapy, radiotherapy, and immunotherapy, have contributed to the improvement of treatment results for various gastroenterological malignancies. However, the prognosis of pancreatic adenocarcinoma (PDAC) remains extremely poor, with a 5‐year survival rate of <10%. Aggressive biological features of early remote metastasis and local invasiveness, no method for early detection or sensitive biomarkers, and resistance to chemotherapy are all implicated as factors responsible for the dismal prognosis. Furthermore, molecular‐targeting agents that are effective for other gastroenterological cancers have been proven invalid for PDAC in most clinical trials